TOBIRA THERAPEUTICS, INC.

🇺🇸United States

Country: 🇺🇸United States

Ownership: Subsidiary

Established: 2006-01-01

Employees: 19

Market Cap: -

Website: http://www.tobiratherapeutics.com

Clinical Trials

Rollover Study of Cenicriviroc for the Treatment of Liver Fibrosis in Participants With Nonalcoholic Steatohepatitis

Phase 2

Terminated

Conditions: Nonalcoholic Steatohepatitis
Non-alcoholic Fatty Liver Disease
Liver Cirrhosis

Interventions: Drug: Cenicriviroc

First Posted Date: 2017-02-23

Last Posted Date: 2022-02-02

Lead Sponsor: Tobira Therapeutics, Inc.

Target Recruit Count: 167

Registration Number: NCT03059446

Locations: 🇩🇪
Universitaetsklinikum Heidelberg - Innere Medizin IV, Heidelberg, Germany
🇩🇪
Uniklinik Koeln, Poliklinik fuer Endokrinologie, Diabetologie und Praeventivmedizin (ZEDP), Koeln, Germany
🇬🇧
Queen Alexandra Hospital, Portsmouth, United Kingdom

and more 68 locations

AURORA: A Study for the Efficacy and Safety of Cenicriviroc (CVC) for the Treatment of Liver Fibrosis in Adults With Nonalcoholic Steatohepatitis (NASH)

Phase 3

Terminated

Conditions: Nonalcoholic Steatohepatitis

Interventions: Drug: Placebo
Drug: Cenicriviroc

First Posted Date: 2017-01-23

Last Posted Date: 2022-03-10

Lead Sponsor: Tobira Therapeutics, Inc.

Target Recruit Count: 1778

Registration Number: NCT03028740

Locations: 🇺🇸
Gastroenterology Associates of Fairfield County, Bridgeport, Connecticut, United States
🇺🇸
Qway Research, LLC, Hialeah, Florida, United States
🇺🇸
Options Health Research, Tulsa, Oklahoma, United States

and more 336 locations

Pharmacokinetic and Safety Study of Cenicriviroc and Acid Reducing Agents When Dosed Alone or in Combination

Phase 1

Completed

Conditions: Healthy

Interventions: Drug: Cenicriviroc
Drug: Famotidine
Drug: Omeprazole

First Posted Date: 2016-02-18

Last Posted Date: 2017-11-24

Lead Sponsor: Tobira Therapeutics, Inc.

Target Recruit Count: 48

Registration Number: NCT02684799

Locations: 🇺🇸
SeaView Research, Inc., Miami, Florida, United States

Pharmacokinetic and Safety Study of Cenicriviroc and HMG-CoA Reductase Inhibitors, Caffeine and Digoxin

Phase 1

Completed

Conditions: Healthy

Interventions: Drug: Digoxin
Drug: Caffeine
Drug: Rosuvastatin
Drug: Atorvastatin
Drug: Simvastatin

First Posted Date: 2016-02-18

Last Posted Date: 2017-11-24

Lead Sponsor: Tobira Therapeutics, Inc.

Target Recruit Count: 36

Registration Number: NCT02685462

PERSEUS: Preliminary Efficacy and Safety of Cenicriviroc in Adult Participants With Primary Sclerosing Cholangitis

Phase 2

Completed

Conditions: Primary Sclerosing Cholangitis

Interventions: Drug: Cenicriviroc 150 mg

First Posted Date: 2016-01-12

Last Posted Date: 2018-10-01

Lead Sponsor: Tobira Therapeutics, Inc.

Target Recruit Count: 24

Registration Number: NCT02653625

Locations: 🇺🇸
Scripps Clinic, La Jolla, California, United States
🇨🇦
University of Calgary, Liver Unit, Calgary, Alberta, Canada
🇨🇦
Toronto University Health Center, Toronto, Ontario, Canada

and more 6 locations

Pharmacokinetic and Safety Study of Cenicriviroc and Pioglitazone, When Dosed Alone or in Combination

Phase 1

Completed

Conditions: Healthy

Interventions: Drug: Cenicriviroc
Drug: Pioglitazone

First Posted Date: 2015-01-19

Last Posted Date: 2015-05-12

Lead Sponsor: Tobira Therapeutics, Inc.

Target Recruit Count: 20

Registration Number: NCT02342067

Locations: 🇺🇸
DaVita Clinical Research, Lakewood, Colorado, United States

ORION: Effects of Cenicriviroc on Insulin Sensitivity in Subjects With Prediabetes or Type 2 Diabetes Mellitus (T2DM) and Suspected NAFLD

Phase 2

Completed

Conditions: Type 2 Diabetes Mellitus
Prediabetic State
Non-alcoholic Fatty Liver Disease

Interventions: Drug: Placebo
Drug: Cenicriviroc 150 mg

First Posted Date: 2015-01-05

Last Posted Date: 2019-10-11

Lead Sponsor: Tobira Therapeutics, Inc.

Target Recruit Count: 45

Registration Number: NCT02330549

Locations: 🇵🇷
Fundacion de Investigacion, San Juan, Puerto Rico
🇺🇸
Gastroenterology Consultants of San Antonio Digestive Research Center, San Antonio, Texas, United States
🇺🇸
San Antonio Military Medical Center, Fort Sam Houston, Texas, United States

Efficacy and Safety Study of Cenicriviroc for the Treatment of Nonalcoholic Steatohepatitis (NASH) in Adult Participants With Liver Fibrosis

Phase 2

Completed

Conditions: Nonalcoholic Steatohepatitis

Interventions: Drug: Cenicriviroc
Drug: Placebo

First Posted Date: 2014-08-15

Last Posted Date: 2019-05-10

Lead Sponsor: Tobira Therapeutics, Inc.

Target Recruit Count: 289

Registration Number: NCT02217475

Phase 1 Study of Multiple-Dose Pharmacokinetics of Cenicriviroc in Subjects With Mild and Moderate Hepatic Impairment

Phase 1

Completed

Conditions: Liver Insufficiency

Interventions: Drug: Cenicriviroc in moderate liver impaired
Drug: Cenicriviroc in mild liver impaired

First Posted Date: 2014-04-22

Last Posted Date: 2014-08-21

Lead Sponsor: Tobira Therapeutics, Inc.

Target Recruit Count: 31

Registration Number: NCT02120547

Locations: 🇺🇸
Clinical Pharmacology of Miami, Inc., Fort Lauderdale, Florida, United States

Study of Dolutegravir (DTG) on PK of Cenicriviroc (CVC), and CVC on PK of DTG & on a Single Dose of Midazolam

Phase 1

Completed

Conditions: HIV-infection/AIDS

Interventions: Drug: Cenicriviroc
Drug: Dolutegravir
Drug: Midazolam

First Posted Date: 2013-04-09

Last Posted Date: 2014-04-09

Lead Sponsor: Tobira Therapeutics, Inc.

Target Recruit Count: 20

Registration Number: NCT01827540

Locations: 🇺🇸
SeaView Research, Inc., Miami, Florida, United States

© Copyright 2024. All Rights Reserved by MedPath

Home Terms & Conditions Privacy Policy